
Business
Starpharma Locks Roche Licensing Frame Worth Up to US64 Million for Cancer Therapies
Melbourne biotech Starpharma signed an exclusive worldwide oncology licence with Genentech, a Roche Group company, locking in US$5.5 million upfront and success payments worth up to US$564 million plus tiered royalties on DEP dendrimer-drug conjugates.
